| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.2 | 0.004 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.004 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.096 | 0.004 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.004 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.096 | 0.004 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.004 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |